Novo Nordisk significantly downgraded its growth expectations for 2025 at the end of July. (Archive photo). Photo: Tom Little/Reuters
Investors seek updates on Novo’s US challenges in report
After a turbulent week with downgrades, a new CEO, and a stock decline of over 30%, Novo Nordisk is set to release its first-half financial report. Investors and analysts are keen on updates regarding the company’s challenges with copycat producers in the US. Last week, Novo Nordisk reduced its...
Get full access to Danish News in English
Gain exclusive access to daily news updates in English pertaining to Denmark with a Ritzau News subscription.
Already a subscriber?